Literature DB >> 29428663

Shengmai San-derived herbal prevents the development of a vulnerable substrate for atrial fibrillation in a rat model of ischemic heart failure.

Jin Ma1, Shiyu Ma2, Chunxia Yin1, Huanlin Wu3.   

Abstract

OBJECTIVE: The study aimed to investigate whether a Shengmai San-derived herbal, Fumai granule (FM), which had a preventive effect on atrial fibrillation (AF) in myocardial infarction (MI)-induced heart failure (HF) rat and to determine the underlying mechanisms. DESIGN AND METHODS: MI was induced by a ligation of the left anterior descending coronary artery. One week after MI surgery, FM was gavaged for 4 weeks. AF inducibility was detected by transesophageal programmed electrical stimulation technology. Multielectrode array measurements, echocardiogram, histology, and western blotting were performed.
RESULTS: The FM-treated group had lower rates of AF inducibility and shorter AF duration compared to the MI group. FM improved the conduction velocity and homogeneity, decreased left atrial positive fibrosis areas and expression of type I and III collagen, inhibited cardiac fibroblast to myofibroblast differential, and increased the expression of connexin 43 and connexin 40 in the left atrium.
CONCLUSIONS: These results suggest that FM reduced the AF inducibility after MI by improving the left atrial conduction function via inhibiting left atrial fibrosis and increasing the expression of connexin, indicating its benefit in preventing the MI-induced vulnerable substrate for AF.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Atrial fibrillation; Cardiac fibrosis; Connexin; Heart failure; Traditional Chinese medicine

Mesh:

Substances:

Year:  2018        PMID: 29428663     DOI: 10.1016/j.biopha.2018.02.013

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  7 in total

Review 1.  Panax ginseng C. A. Meyer as a potential therapeutic agent for organ fibrosis disease.

Authors:  Hao Liu; Chongning Lv; Jincai Lu
Journal:  Chin Med       Date:  2020-11-24       Impact factor: 5.455

2.  Danqi soft capsule prevents infarct border zone remodelling and reduces susceptibility to ventricular arrhythmias in post-myocardial infarction rats.

Authors:  Shiyu Ma; Jin Ma; Xiaoyi Mai; Xujie Zhao; Liheng Guo; Minzhou Zhang
Journal:  J Cell Mol Med       Date:  2019-06-24       Impact factor: 5.310

3.  Isoproterenol Increases Left Atrial Fibrosis and Susceptibility to Atrial Fibrillation by Inducing Atrial Ischemic Infarction in Rats.

Authors:  Shiyu Ma; Jin Ma; Qingqiang Tu; Chaoyang Zheng; Qiuxiong Chen; Weihui Lv
Journal:  Front Pharmacol       Date:  2020-04-15       Impact factor: 5.810

Review 4.  Efficacy and Safety of Fuzi Formulae on the Treatment of Heart Failure as Complementary Therapy: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials.

Authors:  Meng-Qi Yang; Yong-Mei Song; Huan-Yu Gao; Yi-Tao Xue
Journal:  Evid Based Complement Alternat Med       Date:  2019-12-23       Impact factor: 2.629

Review 5.  Mechanism-based targeting of cardiac arrhythmias by phytochemicals and medicinal herbs: A comprehensive review of preclinical and clinical evidence.

Authors:  Danesh Soltani; Bayan Azizi; Roja Rahimi; Azita H Talasaz; Hossein Rezaeizadeh; Ali Vasheghani-Farahani
Journal:  Front Cardiovasc Med       Date:  2022-09-29

6.  Chemical Variations among Shengmaisan-Based TCM Patent Drugs by Ultra-High Performance Liquid Chromatography Coupled with Hybrid Quadrupole Orbitrap Mass Spectrometry.

Authors:  Lulu Xu; Zhanpeng Shang; Yungang Tian; Ming Xiong; Dilaram Nijat; Yuan Wang; Xue Qiao; Min Ye
Journal:  Molecules       Date:  2021-06-30       Impact factor: 4.411

7.  Shensong Yangxin capsule reduces atrial fibrillation susceptibility by inhibiting atrial fibrosis in rats with post-myocardial infarction heart failure.

Authors:  Jin Ma; Chunxia Yin; Shiyu Ma; Huiliang Qiu; Chaoyang Zheng; Qiuxiong Chen; Chunhua Ding; Weihui Lv
Journal:  Drug Des Devel Ther       Date:  2018-10-10       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.